Talha Munir

Ibrutinib‐associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non‐Hodgkin lymphoma: An observational study

Rosa Ruchlemer, Ronen Ben‐Ami, Maskit Bar‐Meir et al. · Mycoses · 2019 · 79 citations · Full text

Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study

William G. Wierda, Nirav N. Shah, Chan Y. Cheah et al. · The Lancet Haematology · 2024 · 31 citations

Hematological Malignancy, Richter Transformation Subgroup, Medicine +11

Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Degrader NX-5948 in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Updated Results from an Ongoing Phase 1a/b Study

Nirav N. Shah, Zulfa Omer, Graham P. Collins et al. · Blood · 2024 · 22 citations

Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia

Talha Munir, Sean Girvan, David A. Cairns et al. · New England Journal of Medicine · 2025 · 15 citations · Full text

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial

Nirav N. Shah, Michael Wang, Lindsey E. Roeker et al. · Haematologica · 2024 · 11 citations · Full text